LEP and endothelial dysfunction: Reductions in adiposity and leptin secretion lead to decreased endothelial leptin signaling, subsequently reducing NO bioavailability mediated by CCR5 and NADPH oxidase 1, directly causing ritonavir-associated endothelial dysfunction [78].